Previous 10 | Next 10 |
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the SVB Securities Annual Global Biopharma Conference. Mana...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the ...
Metacrine ( NASDAQ: MTCR ) and Equillium ( NASDAQ: EQ ) have j ointly agreed to terminate their merger agreement . The deal, announced in September, would have had Equillium ( EQ ) issue stock amounting to ~$26M to fund the acquisition. No reason was given for ...
Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. “Equillium first set out to acquire Metacrine in an all-stock transaction in early 2022, with the intent of adding cash runway in a very di...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patien...
Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M ( ¥ 3.5B); eligible to receive up to approximately $138.5M ( ¥ 18.7B) in option exercise and milestone payments Ono to ...
Equillium press release ( NASDAQ: EQ ): Q3 GAAP EPS of -$0.40 misses by $0.02 . Cash, cash equivalents and short-term investments totaled $44.5 million as of September 30, 2022, compared to $57.6 million as of June 30, 2022. Equillium believes that its cash and investm...
Announced positive interim results from the EQUALISE study of itolizumab in highly proteinuric lupus nephritis patients: by week 28, 83% achieved complete or partial response, and 67% achieved > 80% reduction in urine protein creatinine ratio Announced the pending acquisiti...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that a poster presentation was given over the weekend at ACR Convergence, the...
Phase 2 proof-of-concept study evaluating EQ101 efficacy, safety, tolerability and PK/PD in subjects with alopecia areata over 24 weeks of treatment EQ101 targets IL-2, IL-9, and IL-15, key cytokines known to be upregulated in alopecia areata, and therefore may provide a more ...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...